文献速递贫血与红细胞疾病

红细胞生成刺激剂治疗老年贫血患者:反应与心血管结局

Erythropoiesis-stimulating agents in elderly patients with anemia: response and cardiovascular outcomes.
PubMed 文献 · Blood Adv · 2017-08-17

这项单中心回顾性队列研究纳入2005至2013年间年龄超过60岁、检测过促红细胞生成素(EPO)的贫血患者570例,其中101例接受红细胞生成刺激剂(ESA)治疗。AUE组反应率47%、CKD组54%、其他病因组22%,AUE与其他病因相比调整OR为3.3(95%CI 0.838-13.0)。调整混杂因素后,治疗组与未治疗组心血管事件及无心血管事件生存均无统计学显著差异。

要点

  • AUE组反应率47%、CKD组54%、其他病因组22%,差异未达统计学显著。
  • AUE与其他病因相比反应调整OR为3.3(95%CI 0.838-13.0)。
  • 基线EPO水平<200 IU/L独立预测治疗反应。

核心结论

  • 结果提示ESA可能有效治疗AUE,反应可能与CKD相似。
  • 在研究队列中未能检测到心血管事件统计学显著增加。

研究设计与样本

  • 单中心回顾性队列研究,纳入2005至2013年间年龄超过60岁、检测过EPO的贫血患者570例。
  • 由3名独立评审者依据既定标准将每例患者的贫血归入CKD、骨髓增生异常综合征、AUE或其他病因4组之一。
  • 采用逻辑回归比较治疗反应,反应按骨髓增生异常国际工作组反应标准定义。
  • 采用调整Cox回归分析计算ESA治疗相关的心血管事件风险比。

主要发现

  • 570例患者中101例接受ESA治疗。
  • AUE组反应率47%、CKD组54%、其他病因组22%,差异未达统计学显著但数值上更优。
  • AUE与其他病因相比反应调整OR为3.3(95%CI 0.838-13.0)。
  • 基线EPO水平<200 IU/L独立预测治疗反应。
  • 调整混杂因素后,治疗组与未治疗组心血管事件及无心血管事件生存均无统计学显著差异。

关键数值与推荐

  • 治疗反应按骨髓增生异常国际工作组反应标准定义。
  • 基线EPO水平<200 IU/L独立预测治疗反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A specific cause of anemia cannot be identified in many elderly patients. Erythropoiesis-stimulating agents (ESAs) may play a role in treating these patients with anemia of unknown etiology (AUE). This study examines hemoglobin and cardiovascular outcomes among elderly anemic patients treated with ESAs. We conducted a retrospective cohort study that included all anemic patients older than age 60 years who had erythropoietin (EPO) measured between 2005 and 2013 at a single center. Three independent reviewers used defined criteria to assign each patient's anemia to 1 of 4 groups: chronic kidney disease (CKD), myelodysplastic syndrome, AUE, or other etiology. Logistic regression was used to compare treatment response (defined per the International Working Group response criteria in myelodysplasia). Adjusted Cox regression analysis was used to calculate the cardiovascular event hazard ratios associated with ESA treatment. A total of 570 patients met the inclusion criteria, of whom 101 received ESAs. There was a nonstatistically significant but quantitatively better response in AUE (47%) and CKD (54%) compared with other etiologies (22%). The adjusted odds ratio for response in AUE compared with other etiologies was 3.3 (95% confidence interval, 0.838-13.0). A baseline EPO level <200 IU/L independently predicted treatment response. There was no statistically significant difference in cardiovascular events or cardiovascular event-free survival between the treated and untreated groups after adjusting for confounders. Our results suggest that ESAs may effectively treat AUE, and responses may be similar to those in CKD. We could not detect a statistically significant increase in cardiovascular events in the studied cohort.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gowanlock Z, Sriram S, Martin A, et al. Erythropoiesis-stimulating agents in elderly patients with anemia: response and cardiovascular outcomes. Blood Adv. 2017. PMID: 29296795. doi:10.1182/bloodadvances.2017007559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。